Fennec Pharmaceuticals Inc. (FENC)
Nasdaq · Healthcare · Biotechnology
$10.62+4.12%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $372M
- Forward P/E
- 11.2
- 52-week range
- $5.65 – $13.25
- 52-week change
- +7.59%
- EPS (trailing)
- −$0.12
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $44.6M (−6.09%)
- Net income
- −$9.7B
- Operating margin
- −14.1%
- Diluted EPS
- −$0.34
From the company’s annual report on SEC EDGAR.
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Headquarters: Research Triangle Park, United States · 35 employees · fennecpharma.com